

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/617,888	07/14/2003	Donald Jeffery Zack	01107.00369	3409	
22907 7:	590 12/15/2006		EXAMINER		
BANNER & WITCOFF			LEAVITT, MA	LEAVITT, MARIA GOMEZ	
1001 G STREET N W SUITE 1100			ART UNIT	PAPER NUMBER	
WASHINGTON, DC 20001			1633		
			DATE MAILED: 12/15/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/617,888	ZACK ET AL.		
Examiner	Art Unit		
Maria Leavitt	1633		

	Maria Leavitt	1633	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	lress
THE REPLY FILED 29 November 2006 FAILS TO PLACE THIS	S APPLICATION IN CONDITION F	OR ALLOWANCE.	
1.  The reply was filed after a final rejection, but prior to or on this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a No a Request for Continued Examination (RCE) in compliance time periods:	ving replies: (1) an amendment, aff tice of Appeal (with appeal fee) in (	idavit, or other evider compliance with 37 C	nce, which FR 41.31; or (3)
a) $\boxtimes$ The period for reply expires <u>3</u> months from the mailing date	of the final rejection.		
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I Examiner Note: If box 1 is checked, check either box (a) or the statutory period for reply expire I is checked, check either box (b) or the statutory period for reply expires the statutory period for reply expires on:	ater than SIX MONTHS from the mailin (b). ONLY CHECK BOX (b) WHEN THI	g date of the final reject	ion.
TWO MONTHS OF THE FINAL REJECTION. See MPEP 7			
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of exunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	tension and the corresponding amount shortened statutory period for reply orig r than three months after the mailing da	of the fee. The approprinally set in the final Offi	iate extension fee ice action; or (2) as
2. ☐ The Notice of Appeal was filed on A brief in comp	liance with 37 CFR 41.37 must be	filed within two month	ns of the date of
filing the Notice of Appeal (37 CFR 41.37(a)), or any exte a Notice of Appeal has been filed, any reply must be filed	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of th	ne appeal. Since
AMENDMENTS	hard a da a da a da a de esta a esta a da esta de esta		
<ol> <li>The proposed amendment(s) filed after a final rejection, (a) They raise new issues that would require further co</li> <li>They raise the issue of new matter (see NOTE belo</li> </ol>	nsideration and/or search (see NO		ecause
(c) They are not deemed to place the application in bet appeal; and/or			the issues for
(d) They present additional claims without canceling a	corresponding number of finally rej	ected claims.	
NOTE: (See 37 CFR 1.116 and 41.33(a)).	24. Soo attached Nation of Non Ca		(DTOL 224)
<ol> <li>The amendments are not in compliance with 37 CFR 1.13</li> <li>Applicant's reply has overcome the following rejection(s)</li> </ol>		impliant Amendment	(PTOL-324).
<ol> <li>Newly proposed or amended claim(s) would be all non-allowable claim(s).</li> </ol>		timely filed amendme	ent canceling the
7.  For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is provided the status of the claim(s) is (or will be) as follows:		ll be entered and an e	explanation of
Claim(s) allowed:			
Claim(s) objected to:			
Claim(s) rejected: <u>10, 12-19</u> . Claim(s) withdrawn from consideration:	•	•	
AFFIDAVIT OR OTHER EVIDENCE			•
B. The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e).			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appe	al and/or appellant fai	ils to provide a
10. ☐ The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after e	ntry is below or attach	ned.
11.   The request for reconsideration has been considered bu  See Continuation Sheet.		n condition for allowa	nce because:
12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08) Paper No(s)		
13.  Other:	•	•	

Continuation of 11. does NOT place the application in condition for allowance because: Claims 10, and 12-19 remain rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Applicant argues that the term "reducing" has to be read in light of the supporting disclosure and as such is directed towards the cell death which is associated with a neurological disorder. The term remains indefinite, as there is not reference to what stage of cell neuronal cell death the term refers to.

Moreover, claims Claims 10, 12-19, remain rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or to which it is most nearly connected, to make an/or use the invention. Applicant states that thirty-nine references attest to the ability of those skilled in the art in July 2002 to transfer and express exogenous genes effectively in neurons in vivo. The most relevant prior art was examined in the prior office action as suggested by the Applicant. Though prior art teach that exogenous genes can be expressed in vivo, consistently, the prior art of record discloses relevant issues related to the treatment of any disease that have to be examined for a method of reducing neuronal cell death as broadly claimed. Such issues include: efficient-non toxic vectors, safe and efficient gene transfer, targeting of specific cells for treatment of specific type of disease and stability of expression for any neuronal disease to treated by reducing or preventing neuronal cell death. As the result, given the unpredictability of the art and the lack of working example in the instant specification, particularly when taken with the lack of guidance in the specification, it would have required undue experimentation to practice the instant method to identify an enormous number of methods as broadly or generically claimed, with a resultant identification of a method for reducing neuronal cell death in a mammal as broadly claimed.